リバビリン

リバビリン · 1-[3-(アミノカルボニル)-1H-1,2,4-トリアゾール-1-イル]-1-デオキシ-β-D-リボフラノース · ビラミド · コペガス · リバミジル · ビラゾール · 1-β-D-リボフラノシル-1H-1,2,4-トリアゾール-3-カルボアミド · ビロナ

https://huagongshe.com/ja/chemical/37542

識別子と物理属性

CAS No.	36791-04-5
分子式	C8H12N4O5
平均分子量	244.2 g/mol
単同位体質量	244.0807695 g/mol
SMILES	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
InChIKey	IWUCXVSUMQZMFG-AFCXAGJDSA-N
PubChem CID	37542
ChEMBL	CHEMBL1643
ChEBI	CHEBI:63580
EC No.	636-825-3
DTXSID	DTXSID8023557
現地名	リバビリン

化学・物理的性質

XLogP	-1.8
極性表面積	144
水素結合供与体数	4
水素結合受容体数	7
回転可能結合数	3
重原子数	17
形式電荷	0
複雑度	304
LogP（分配係数）	-1.85log Kow = -1.85-2.6
臭い	Odorless
味	Tasteless
Color/Form	ColorlessWhite crystalline powder
溶解度	greater than or equal to 100 mg/mL at 66 °F (NTP, 1992)SolubleWater-solubleSlightly soluble in alcohol.In water, 142 mg/mL at 25 °C3.32e+01 g/L水に溶けやすく、エタノール (96%) に溶けにくく、ジクロロメタンに溶けにくい。ポリモーフィズム (5.9) を示します。>=10 g/100 mL で 19 ºC
Decomposition	When heated to decomposition it emits toxic fumes of /nitrogen oxides/.
融点	345 to 349 °F (NTP, 1992)174-176 °C166-168 °C (aq ethanol)174-176 °C (ethanol).174 - 176 °C174-176°C
Optical Rotation	Specific optical rotation: -36.5 deg at 25 °C/D
Physical Description	Ribavirin is a white powder. Exists in two polymorphic forms. (NTP, 1992)Solid
Stability/Shelf Life	Ribavirin solutions contain no preservatives and are stable for 24 hr when stored under sterile conditions at a room temperature of 20-30 °C. Following addition of the reconstituted solution to the reservoir of the SPAG-2 and further dilution with sterile water for injection or inhalation (additive free), the ribavirin solution for nebulization should be discarded within 24 hr.
Collision Cross Section	152.15 Å² [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]149.81 Å² [M+H]+ [CCS Type: TW153.31 Å² [M+K]+ [CCS Type: TW142.23 Å² [M+H-H2O]+ [CCS Type: TW
Other Experimental Properties	Exists in two polymorphic forms
比旋光度	D25 -36.5° (c = 1 in water)D20 -38° (c = 1 in water)
沸点	387.12°C (rough estimate)
密度	1.4287 (rough estimate)
屈折率	-36 ° (C=1, H2O)
貯蔵条件	2-8°C
外観・状態	白い固体
pKa（酸解離定数）	12.95±0.70(Predicted)
色	白い
Merck	14,8198
BCS Class	3
安定性	DMSOまたは蒸留水の溶液で-20°Cで最大3か月保存できます.
主な用途	医薬品（低分子化合物）
InChI	1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChIKey	IWUCXVSUMQZMFG-AFCXAGJDSA-N
SMILES	NC(=O)c1ncn(n1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O
LogP（分配係数）	-2.260 (est)
CAS データベース	36791-04-5
EPAの化学物質情報	Ribavirin (36791-04-5)

化学的特性

Colourless Solid

安全性と法規制

GHS 分類	DangerH317 (47.4%): May cause an allergic skin reaction [Warning Sensitization, Skin]H319 (49.1%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (57.9%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]H341 (58.8%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]H360 (51.8%): May damage fertility or the unborn child [Danger Reproductive toxicity]H361 (48.2%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H373 (48.2%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]H412 (47.4%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]P203, P260, P261, P264+P265, P271, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 114 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
規制情報	Hazard Traits - Developmental ToxicityReproductive ToxicityAuthoritative List - Prop 65Report - regardless of intended function of ingredient in the product1H-1,2,4-Triazole-3-carboxamide, 1-.beta.-D-ribofuranosyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
火災危険	Flash point data for this chemical are not availablehowever, it is probably combustible. (NTP, 1992)
健康有害性	SYMPTOMS: Symptoms of exposure to this compound may include headache, abdominal cramps, fatigue, reversible anemia and elevation of bilirubin concentrations. In infants, it may cause deterioration of respiratory function. In adults, it may cause chronic obstructive lung disease or asthma, dyspnea, chest soreness, pulmonary function deterioration, bacterial pneumonia, pneumothorax, apnea, ventilator dependence, cardiac arrest, hypotension, digitalis toxicity, reticulocytosis, rash and conjunctivitis.

用途

ウィルス RNA ポリメラーゼを阻害し、ウィルスの増殖阻害作用を示します。

用途

リバビリン（Ribavirin）は、抗ウイルス薬の一つで、主にC型肝炎やウイルス性出血熱等の治療で施行されている。

使用

Ribavirin is a guanosine analog with antiviral properties against DNA and RNA viruses, including respiratory syncytial virus, hepatitis C, and influenza. It acts as a prodrug that can be activated by either mono- or tri-phosphorylation by cellular kinases. These phosphorylated derivatives of ribavirin have diverse effects on both cellular and viral enzymes, resulting in suppression of viral replication.

一般的な説明

Ribavirin is 1-β-D-ribofuranosyl-1,2,4-thiazole-3-carboxamide.The compound is a purine nucleoside analog with amodified base and a D-ribose sugar moiety.Ribavirin inhibits the replication of a very wide variety ofRNA and DNA viruses,68 including orthomyxoviruses,paramyxoviruses, arenaviruses, bunyaviruses, herpesviruses,adenoviruses, poxvirus, vaccinia, influenza virus(types A and B), parainfluenza virus, and rhinovirus. In spiteof the broad spectrum of activity of ribavirin, the drug hasbeen approved for only one therapeutic indication—thetreatment of severe lower respiratory infections caused byRSV in carefully selected hospitalized infants and youngchildren.